2017/08/07: Under the terms of the Agreement, Plexus Ventures will develop a development strategy for drug candidates and will hold meetings with potential partners. In the event of significant clinical progress and consent of the parties to the drug development strategy, Plexus Ventures will take steps to acquire partners for development or licensees or to sell the Company's innovative drug distribution rights. The choice of a specific strategy for the product will be related to the market and investment characteristics of the drug's development. Licensing or selling of rights to distribution of innovative medicines Celon Pharma SA may take place at the turn of 2018/2019.

Dr. Maciej Wieczorek, President of the Management Board of Celon Pharma SA: The agreement with Plexus Ventures confirms the legitimacy of further development of selected candidates for drugs that have the potential of being the first in their therapeutic class or having significant competitive characteristics. Developed products can achieve global sales potential of more than $ 0.5 billion per year and some of them over $ 2 billion per year.

At the same time, the Company has plans for sustainable, independent commercialization of its own specialized medicines on the world markets.

About Plexus Ventures

Now in its 27th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia, Sao Paulo and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.